Latest Nasal administration Stories
Current Investors and Management Increase Support for OptiNose and the Company's Breakthrough New Product, OPN-375 YARDLEY, Pa., Aug.
ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered(TM)
AVP-825, Using OptiNose's Patented Bi-Directional(TM) Breath Powered(TM) Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the
DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6d9skh/drug_delivery_in) has announced the addition of a new report
AVP-825 uses novel Breath Powered(TM) drug delivery to treat migraine YARDLEY, Pa., Jan.